Klinik für Hämatologie, Onkologie u. klinische Immunology Heinrich-Heine-Universität Moorenstr. 5D-40225 Düsseldorf, Germany.
Biol Blood Marrow Transplant. 2010 Jan;16(1 Suppl):S30-6. doi: 10.1016/j.bbmt.2009.10.017. Epub 2009 Oct 24.
Although allogeneic hematopoietic cell transplantation (HCT) is the only proven curative treatment for myelodysplastic syndromes (MDS), it is only used to treat a minority of MDS patients. The majority of patients are too old or suffer from comorbidities rendering allogeneic HCT too risky. Alternative treatment strategies for patients with higher risk MDS try to alter the natural course of disease by preventing or delaying leukemic transformation. In patients with lower risk MDS, treatment is mainly focused on maintaining or improving the quality of life.
虽然异基因造血细胞移植(HCT)是唯一被证实可治愈骨髓增生异常综合征(MDS)的方法,但它仅用于治疗少数 MDS 患者。大多数患者年龄太大或患有合并症,使异基因 HCT 风险过高。对于高危 MDS 患者的替代治疗策略旨在通过预防或延迟白血病转化来改变疾病的自然进程。对于低危 MDS 患者,治疗主要集中在维持或提高生活质量上。